Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00025984
DRKS00025984
Completed
Not Applicable

Clinical study to investigate the safe and effective use of Stethoglove® by health care professionals under real-life conditions

Stethoglove GmbH0 sites54 target enrollmentNovember 18, 2021
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPlacing a physical barrier between the patient and the stethoscope is one way to improve the protection of patients from germ transmission through the stethoscope.

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Placing a physical barrier between the patient and the stethoscope is one way to improve the protection of patients from germ transmission through the stethoscope.
Sponsor
Stethoglove GmbH
Enrollment
54
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 18, 2021
End Date
March 11, 2022
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Sponsor
Stethoglove GmbH

Eligibility Criteria

Inclusion Criteria

  • •Adult male and female patients (\=18 years) elected for cardiac surgery
  • •\- Ability to understand the purpose and risks of the clinical study and to provide signed and dated informed consent

Exclusion Criteria

  • •\- Known allergy or contact sensitization against the Stethoglove® material (thermoplastic urethane, TPU)
  • •\- Patients with known HIV, Hepatitis B or C infections
  • •\- Legal incapacity or limited legal capacity
  • •\- Participation in an interventional clinical trial within 30 days prior to enrollment
  • •\- Employees of the sponsor or patients who are employees or relatives of the users
  • •\- Patients committed to an institution by virtue of an order issued either by the judicial or the administrative authorities

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1 Level: LLT Classification code 10064859 Term: Primary immunodeficiency syndrome
EUCTR2007-002611-27-GBOctapharma AG5
Active, not recruiting
Phase 1
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immunodeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndrome
EUCTR2007-002611-27-FROctapharma AG5
Active, not recruiting
Not Applicable
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in Primary Immunodeficiency Diseases (PID) - NAPrimary Immundeficiency Diseases (PID)MedDRA version: 9.1Level: LLTClassification code 10064859Term: Primary immunodeficiency syndrome
EUCTR2007-002611-27-DEOctapharma AG45
Completed
Not Applicable
Clinical study to evaluate the efficacy, safety and kinetics of Octagam® 10% for replacement therapy in primary immunodeficiency diseasesPrimary immunodeficiency diseases (PID)Haematological DisordersOther immunodeficiencies
ISRCTN63491981Octapharma AG (Switzerland)45
Completed
Phase 2
Role of GastriCare in Digestive wellbeingHealth Condition 1: null- Subjects who have clinical symptoms of dyspepsia, upper abdominal pain, heart burn, bloating, indigestion, flatulence, abdominal distension, belching and fullness after meal
CTRI/2018/04/013249The Himalaya Drug Company60